We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch
Read MoreHide Full Article
Key Takeaways
Pfizer's non-oncology results will highlight performance across Primary Care and Specialty Care in Q3.
Eliquis demand may boost sales, while lower COVID-19 demand will weigh on revenues.
Vyndaqel sales may rise on international strength, while Xeljanz and Enbrel sales likely continue to decline.
Pfizer (PFE - Free Report) will announce its third-quarter 2026 earnings on Nov. 3, and investors will be watching the performance of its oncology business closely, as the segment generates nearly 27% of the company's total revenues. Its key cancer medicines include Ibrance, Xtandi, Lorbrena, Braftovi/Mektovi and Padcev.
Apart from oncology, Pfizer has a broad portfolio spanning primary care, vaccines, inflammation and immunology, rare diseases and other specialty therapies. These businesses are organized under the company's Primary Care and Specialty Care segments.
Here’s a closer look at the expected third-quarter performance of Pfizer’s therapies across these two non-oncology business segments.
In Primary Care, alliance revenues and direct sales from Bristol-Myers (BMY - Free Report) for the blood thinner Eliquis are likely to have risen, driven by higher demand trends globally, partially offset by price and generic erosion in some ex-U.S. markets. As regards sales of key vaccine Prevnar, higher sales in ex-U.S. markets are likely to have been offset by the impact of lower demand in the United States.
Pfizer records direct sales and alliance revenues from its partner, BioNTech (BNTX - Free Report) , for the COVID-19 vaccine, Comirnaty. Revenues from Pfizer/BioNTech’s Comirnaty are likely to have declined in the third quarter due to lower U.S. utilization following narrower vaccination recommendations. Sales of the antiviral pill for COVID, Paxlovid, should also have declined due to lower infection rates, which hurt demand trends and lower international government purchases.
Sales of respiratory syncytial virus (RSV) vaccine, Abrysvo, are likely to have gained from launch uptake in some international markets, although vaccination recommendations and competition may constrain growth in United States. Favorable timing of deliveries in some international markets and favorable buying patterns in the United States benefitted sales in the second quarter, which may have reversed in the third quarter. Sales of migraine drug, Nurtec ODT/Vydura, are likely to have benefited from strong demand and prescription growth in the United States.
In the Specialty Care unit, sales of Vyndaqel are expected to have risen, as higher sales in international markets may offset lower revenues in the United States due to the impact of price erosion as a result of new payer contracts in the United States.
Sales of Xeljanz and Enbrel may have declined due to competitive and pricing pressures. In contrast, newer medicines such as Cibinqo could benefit from continued market uptake.
Pfizer’s Key Competitors
In inflammation & immunology, Pfizer’s key competitors include AbbVie, Johnson & Johnson, Amgen and Novartis. In areas such as diabetes, cardiovascular disease, obesity, and other chronic conditions, Pfizer faces competition from Eli Lilly, Novo Nordisk, Merck (MRK - Free Report) , AstraZeneca and Sanofi. In vaccines, it competes primarily with Merck, GSK, Sanofi and Moderna.
View the Zacks #1 Rank List
Image: Bigstock
Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch
Key Takeaways
Pfizer (PFE - Free Report) will announce its third-quarter 2026 earnings on Nov. 3, and investors will be watching the performance of its oncology business closely, as the segment generates nearly 27% of the company's total revenues. Its key cancer medicines include Ibrance, Xtandi, Lorbrena, Braftovi/Mektovi and Padcev.
Apart from oncology, Pfizer has a broad portfolio spanning primary care, vaccines, inflammation and immunology, rare diseases and other specialty therapies. These businesses are organized under the company's Primary Care and Specialty Care segments.
Here’s a closer look at the expected third-quarter performance of Pfizer’s therapies across these two non-oncology business segments.
In Primary Care, alliance revenues and direct sales from Bristol-Myers (BMY - Free Report) for the blood thinner Eliquis are likely to have risen, driven by higher demand trends globally, partially offset by price and generic erosion in some ex-U.S. markets. As regards sales of key vaccine Prevnar, higher sales in ex-U.S. markets are likely to have been offset by the impact of lower demand in the United States.
Pfizer records direct sales and alliance revenues from its partner, BioNTech (BNTX - Free Report) , for the COVID-19 vaccine, Comirnaty. Revenues from Pfizer/BioNTech’s Comirnaty are likely to have declined in the third quarter due to lower U.S. utilization following narrower vaccination recommendations. Sales of the antiviral pill for COVID, Paxlovid, should also have declined due to lower infection rates, which hurt demand trends and lower international government purchases.
Sales of respiratory syncytial virus (RSV) vaccine, Abrysvo, are likely to have gained from launch uptake in some international markets, although vaccination recommendations and competition may constrain growth in United States. Favorable timing of deliveries in some international markets and favorable buying patterns in the United States benefitted sales in the second quarter, which may have reversed in the third quarter. Sales of migraine drug, Nurtec ODT/Vydura, are likely to have benefited from strong demand and prescription growth in the United States.
In the Specialty Care unit, sales of Vyndaqel are expected to have risen, as higher sales in international markets may offset lower revenues in the United States due to the impact of price erosion as a result of new payer contracts in the United States.
Sales of Xeljanz and Enbrel may have declined due to competitive and pricing pressures. In contrast, newer medicines such as Cibinqo could benefit from continued market uptake.
Pfizer’s Key Competitors
In inflammation & immunology, Pfizer’s key competitors include AbbVie, Johnson & Johnson, Amgen and Novartis. In areas such as diabetes, cardiovascular disease, obesity, and other chronic conditions, Pfizer faces competition from Eli Lilly, Novo Nordisk, Merck (MRK - Free Report) , AstraZeneca and Sanofi. In vaccines, it competes primarily with Merck, GSK, Sanofi and Moderna.